Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Fuji
Colorcon
QuintilesIMS
Daiichi Sankyo

Generated: May 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,900,221

« Back to Dashboard

Which drugs does patent 6,900,221 protect, and when does it expire?

Patent 6,900,221 protects TARCEVA and is included in one NDA.

Protection for TARCEVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-six patent family members in thirty-seven countries.

Summary for Patent: 6,900,221
Title: Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
Abstract:The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
Inventor(s): Norris; Timothy (Gales Ferry, CT), Raggon; Jeffrey W. (North Stonington, CT), Connell; Richard D. (East Lyme, CT), Moyer; James D. (East Lyme, CT), Morin; Michael J. (Waterford, CT), Kajiji; Shama M. (Mystic, CT), Foster; Barbara A. (Mystic, CT), Ferrante; Karen J. (East Greenwich, RI), Silberman; Sandra L. (Randolph, NJ)
Assignee: OSI Pharmaceuticals, Inc. (Melville, NY)
Application Number:09/711,272
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,900,221
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,900,221
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Process;

Drugs Protected by US Patent 6,900,221

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-001 Nov 18, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-002 Nov 18, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-003 Nov 18, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Merck
Farmers Insurance
AstraZeneca
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.